相似文献
1
With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study.
Blood. 2019 Jun 13;133(24):2615-2618. doi: 10.1182/blood.2019000406. Epub 2019 Apr 19.
2
Where you live can impact your cancer risk: a look at multiple myeloma in New York City.
Ann Epidemiol. 2020 Aug;48:43-50.e4. doi: 10.1016/j.annepidem.2020.05.005. Epub 2020 May 15.
3
Ethnic differences in blood pressure control among men at Veterans Affairs clinics and other health care sites.
Arch Intern Med. 2005 May 9;165(9):1041-7. doi: 10.1001/archinte.165.9.1041.
4
Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis.
Cancer. 2016 Feb 15;122(4):618-25. doi: 10.1002/cncr.29771. Epub 2015 Nov 13.
5
Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups.
Br J Haematol. 2012 Jul;158(1):91-8. doi: 10.1111/j.1365-2141.2012.09124.x. Epub 2012 Apr 26.
6
Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.
Cancer Med. 2017 Dec;6(12):2876-2885. doi: 10.1002/cam4.1246. Epub 2017 Nov 3.
7
Racial differences in mortality among men hospitalized in the Veterans Affairs health care system.
JAMA. 2001 Jan 17;285(3):297-303. doi: 10.1001/jama.285.3.297.
8
Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities.
Cancer. 2018 Apr 15;124(8):1710-1721. doi: 10.1002/cncr.31237. Epub 2018 Jan 23.
9
The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma.
Haematologica. 2006 Oct;91(10):1410-3. Epub 2006 Sep 7.
10
Ethnic Disparities in Emergency Severity Index Scores among U.S. Veteran's Affairs Emergency Department Patients.
PLoS One. 2015 May 29;10(5):e0126792. doi: 10.1371/journal.pone.0126792. eCollection 2015.
引用本文的文献
1
Frequent Missed Opportunities for Earlier Diagnosis of Advanced-Stage Colorectal or Lung Cancer.
JAMA Intern Med. 2025 Jul 21. doi: 10.1001/jamainternmed.2025.2875.
2
Temporal patterns in US population-based patient survival among adults treated with chemotherapy and/or immunotherapy for multiple myeloma, 2000-2020.
Br J Haematol. 2025 Jun 10. doi: 10.1111/bjh.20192.
3
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma.
Blood Neoplasia. 2024 Dec 26;2(1):100065. doi: 10.1016/j.bneo.2024.100065. eCollection 2025 Feb.
4
Social determinants of health and their impact on frontline treatment patterns among Medicare Advantage members with newly diagnosed multiple myeloma.
J Manag Care Spec Pharm. 2025 Jun;31(6):603-612. doi: 10.18553/jmcp.2025.31.6.603.
5
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study.
Blood Cancer J. 2024 Dec 20;14(1):223. doi: 10.1038/s41408-024-01206-4.
6
Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma.
Blood Adv. 2025 Jan 14;9(1):78-88. doi: 10.1182/bloodadvances.2024014125.
7
Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel.
Blood Cancer J. 2024 Aug 27;14(1):149. doi: 10.1038/s41408-024-01129-0.
8
Understanding Myeloma-Related Information Needs and Communication Preferences Within Black American Communities: An Exploratory Study.
J Cancer Educ. 2025 Feb;40(1):124-131. doi: 10.1007/s13187-024-02480-3. Epub 2024 Aug 16.
9
The American Society of Hematology Health Equity Compendium: examining health equity across the Blood journals.
Blood Adv. 2024 Sep 10;8(17):4616-4624. doi: 10.1182/bloodadvances.2024013633.
10
Racial and Ethnic Disparity for Cancer Mortality in General and Single-Payer Healthcare Systems in the United States.
J Racial Ethn Health Disparities. 2024 Jul 2. doi: 10.1007/s40615-024-02077-y.
本文引用的文献
1
Biological determinants of health disparities in multiple myeloma.
Blood Cancer J. 2018 Aug 28;8(9):85. doi: 10.1038/s41408-018-0118-z.
2
Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials.
Blood Cancer J. 2018 Jul 6;8(7):67. doi: 10.1038/s41408-018-0102-7.
3
Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.
Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):219-224. doi: 10.1016/j.clml.2018.01.005. Epub 2018 Jan 31.
4
Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications.
Blood Adv. 2018 Jan 23;2(2):116-119. doi: 10.1182/bloodadvances.2017010512.
5
Cancer statistics, 2018.
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
6
Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States.
Blood Adv. 2017 Jan 4;1(4):282-287. doi: 10.1182/bloodadvances.2016002493. eCollection 2017 Jan 10.
7
Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases.
PLoS Genet. 2017 Nov 22;13(11):e1007087. doi: 10.1371/journal.pgen.1007087. eCollection 2017 Nov.
8
Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.
Cancer Med. 2017 Dec;6(12):2876-2885. doi: 10.1002/cam4.1246. Epub 2017 Nov 3.
9
Racial and ethnic disparities in hematologic malignancies.
Blood. 2017 Oct 12;130(15):1699-1705. doi: 10.1182/blood-2017-04-778225. Epub 2017 Jul 19.
10
Racial disparities in treatment use for multiple myeloma.
Cancer. 2017 May 1;123(9):1590-1596. doi: 10.1002/cncr.30526. Epub 2017 Jan 13.
Zotero 插件